Author: Ravi Shankar

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company’s novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), in combination with acalabrutinib, for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

BTDs are granted to innovative drugs or modified new drugs intended for the prevention or treatment of serious, life-threatening diseases or conditions that severely impair quality of life, for which there is no effective treatment, or where sufficient existing evidence demonstrates significant clinical advantages over currently available treatment options. Drug candidates that are granted BTDs receive priority from the CDE for communications and development guidance to accelerate drug development. Furthermore, if the applicant meets the relevant conditions after evaluation, it may apply for Priority Review status and conditional approval when submitting a New Drug Application (NDA) in China. Overall, the BTD pathway is designed to accelerate the development and review of innovative drugs and modified new drugs that offer significant clinical value or address urgent unmet clinical needs.

CLL/SLL is a clonal proliferative malignancy of B lymphocytes that predominantly affects older adults, with more than 100,000 new cases worldwide each year.¹ In recent years, the incidence of CLL/SLL in China has been increasing, with some patients presenting at a younger age and with more aggressive disease.²

In CLL/SLL, immunochemotherapy and BTK inhibitors have been used as first-line treatment options and have achieved favorable response rates and survival outcomes, although certain limitations remain. Immunochemotherapy has limited efficacy in some patients, particularly in those with high-risk features such as del(17p)/TP53 mutations, complex karyotypes, and unmutated IGHV. BTK inhibitor monotherapy, which is an approved standard of care treatment, also has limitations, including insufficient depth of response and concerns regarding long-term safety, and requires continuous treatment. Once treatment fails, patients have very limited subsequent treatment options, with generally poor outcomes. Therefore, there remains an urgent clinical need for fixed-duration combination strategies that improve efficacy and depth of response while reducing adverse events.

Lisaftoclax is a novel, oral, selective Bcl-2 inhibitor developed by Ascentage Pharma. In July 2025, lisaftoclax was approved in China for the treatment of adult patients with CLL/SLL who had previously received at least one systemic therapy including a BTK inhibitor. Lisaftoclax is the first China-developed Bcl-2 inhibitor approved in China and the second Bcl-2 inhibitor approved globally. Ascentage Pharma is currently conducting four global registrational Phase III trials of lisaftoclax. One of these studies, GLORA-2, is a global registrational Phase III trial evaluating the clinical potential of lisaftoclax in combination with acalabrutinib as a first-line treatment for CLL/SLL.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, “This BTD recognizes the clinical potential of Lisaftoclax in combination with acalabrutinib for patients with treatment-naïve CLL/SLL and the urgent unmet need in this setting. Moving forward, we are continuing to accelerate the global clinical development of lisaftoclax across relevant indications and are striving to bring this treatment to more patients as quickly as possible.”

References

1. Yao, Y., Lin, X., Li, F., et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022 Jan 11;21(1):4. DOI: 10.1186/s12938-021-00973-6
2. 刘澎. 复旦大学附属中山医院慢性淋巴细胞白血病/小淋巴细胞淋巴瘤诊疗规范（2018）[J].中国临床医学, 2018, 25(1): 157-160. DOI: 10.12015/j. issn.1008-6358.2018.20180

In the United States, lisaftoclax (APG-2575) is an investigational compound and has not been approved by the US FDA. The combination of lisaftoclax and acalabrutinib is investigational and has not been approved in any market.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA- cleared GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:

Ascentage Pharma
IR@ascentage.com
+1 (301) 792-6286

astr partners
brian.korb@astrpartners.com
+1 (917) 653-5122

TORONTO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Matachewan Consolidated Mines, Limited (TSXV: MCMA) (“Matachewan”) and McChip Resources Inc. (TSXV: MCS) (“McChip” and, together with Matachewan, the “Acquirors”) announce that, on October 19, 2026, they acquired an aggregate of 42,675,809 common shares (the “Common Shares”) of Labrador Gold Corp. (the “Company”) in connection with the closing of the first tranche (the “First Tranche”) of the Company’s non-brokered private placement (the “Offering”). The Company’s head office is located at the Canadian Venture Building, 82 Richmond Street East, Toronto, Ontario M5C 1P1. The address of each of Matachewan and McChip is 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9. 

The First Tranche consisted of the issuance by the Company of 42,675,809 Common Shares on a “flow-through” basis at a price of $0.05 per Common Share, for aggregate gross proceeds of $2,133,790.45. Matachewan acquired ownership of 21,337,905 Common Shares for total consideration of $1,066,895.25, and McChip acquired ownership of 21,337,904 Common Shares for total consideration of $1,066,895.20, in each case at a price of $0.05 per Common Share pursuant to a subscription agreement with the Company. The Common Shares were issued from treasury by way of private placement, and the acquisitions did not take place on any marketplace. 

Immediately prior to closing of the First Tranche, neither Matachewan nor McChip owned or controlled any Common Shares. Immediately following closing of the First Tranche, Matachewan owns and controls 21,337,905 Common Shares and McChip owns and controls 21,337,904 Common Shares, each representing approximately 9.995% of the issued and outstanding Common Shares on a non-diluted basis, an increase of approximately 9.995% for each Acquiror. The Acquirors are joint actors and together own and control 42,675,809 Common Shares, representing approximately 19.99% of the issued and outstanding Common Shares on a non-diluted basis. 

The Acquirors hold their Common Shares as part of a strategic investment in the Company. In connection with the First Tranche, Raymond D. Harari was appointed as a director of the Company and is anticipated to be appointed President at a later date. The Acquirors are entitled to, and intend to, subscribe for additional Common Shares on a non-flow-through basis in the second tranche of the Offering, pursuant to their subscription agreements with the Company and the investor rights agreement among the Company and the Acquirors dated October 19, 2026 (the “Investor Rights Agreement“), such that they collectively hold approximately 19.99% of the issued and outstanding Common Shares following its completion, subject to the cap in the Investor Rights Agreement, TSXV acceptance and applicable law.

Each Acquiror intends to review its holdings in the Company on a continuing basis and may purchase or sell Common Shares in the future, including in private transactions (and, if applicable, through a marketplace), in each case depending on a number of factors. The Acquirors may formulate other purposes, plans or proposals regarding the Company or any of its securities or may change their intentions with respect to any and all matters. The Acquirors, in consultation with the Company, may also propose or seek to effect certain corporate transactions involving the Company. 

The acquisition of the Common Shares did not constitute a formal bid, and the Acquirors did not rely on any exemption from the formal bid requirements in connection with the acquisition. 

Each of Matachewan and McChip will file an early warning report in accordance with applicable securities laws, which will be available under the Company’s profile on SEDAR+ at www.sedarplus.ca. A copy of each early warning report may also be obtained by contacting Zachary Goldenberg, Chief Executive Officer of Matachewan and McChip, at 647-987-5083. 

About Matachewan Consolidated Mines, Limited 

Matachewan is a Canadian natural resource company incorporated in 1933 and headquartered in Toronto, Ontario. Matachewan maintains exposure to the natural resource sector through investments in mineral and other resource-related opportunities. Its common shares trade on the TSXV under the symbol MCMA.

About McChip Resources Inc. 

McChip is a Canadian natural resource company incorporated in 1935 and headquartered in Toronto, Ontario. McChip maintains exposure to the natural resource sector through investments in mineral and other resource-related opportunities. Its common shares trade on the TSX Venture Exchange under the symbol MCS.

For additional information, please contact: 

Matachewan Consolidated Mines, Limited: Zachary Goldenberg, Chief Executive Officer, T: 647-987-5083, E: zach@libertyvp.co

McChip Resources Inc.: Zachary Goldenberg, Chief Executive Officer, T: 647-987-5083, E: zach@libertyvp.co

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Forward-Looking Statements 

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements relating to the Acquirors’ intention to participate in the second tranche of the Offering and their future intentions with respect to their holdings in the Company. Forward-looking information is based on assumptions and is subject to risks and uncertainties, many of which are beyond the control of the Acquirors, that could cause actual results to differ materially, including that the second tranche of the Offering may not be completed on the terms anticipated or at all. Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable securities laws, the Acquirors disclaim any obligation to update or revise any forward-looking information. 

TORONTO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Matachewan Consolidated Mines, Limited (TSXV: MCMA) (“Matachewan”) and McChip Resources Inc. (TSXV: MCS) (“McChip” and, together with Matachewan, the “Acquirors”) announce that, on October 19, 2026, they acquired an aggregate of 42,675,809 common shares (the “Common Shares”) of Labrador Gold Corp. (the “Company”) in connection with the closing of the first tranche (the “First Tranche”) of the Company’s non-brokered private placement (the “Offering”). The Company’s head office is located at the Canadian Venture Building, 82 Richmond Street East, Toronto, Ontario M5C 1P1. The address of each of Matachewan and McChip is 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9. 

The First Tranche consisted of the issuance by the Company of 42,675,809 Common Shares on a “flow-through” basis at a price of $0.05 per Common Share, for aggregate gross proceeds of $2,133,790.45. Matachewan acquired ownership of 21,337,905 Common Shares for total consideration of $1,066,895.25, and McChip acquired ownership of 21,337,904 Common Shares for total consideration of $1,066,895.20, in each case at a price of $0.05 per Common Share pursuant to a subscription agreement with the Company. The Common Shares were issued from treasury by way of private placement, and the acquisitions did not take place on any marketplace. 

Immediately prior to closing of the First Tranche, neither Matachewan nor McChip owned or controlled any Common Shares. Immediately following closing of the First Tranche, Matachewan owns and controls 21,337,905 Common Shares and McChip owns and controls 21,337,904 Common Shares, each representing approximately 9.995% of the issued and outstanding Common Shares on a non-diluted basis, an increase of approximately 9.995% for each Acquiror. The Acquirors are joint actors and together own and control 42,675,809 Common Shares, representing approximately 19.99% of the issued and outstanding Common Shares on a non-diluted basis. 

The Acquirors hold their Common Shares as part of a strategic investment in the Company. In connection with the First Tranche, Raymond D. Harari was appointed as a director of the Company and is anticipated to be appointed President at a later date. The Acquirors are entitled to, and intend to, subscribe for additional Common Shares on a non-flow-through basis in the second tranche of the Offering, pursuant to their subscription agreements with the Company and the investor rights agreement among the Company and the Acquirors dated October 19, 2026 (the “Investor Rights Agreement“), such that they collectively hold approximately 19.99% of the issued and outstanding Common Shares following its completion, subject to the cap in the Investor Rights Agreement, TSXV acceptance and applicable law.

Each Acquiror intends to review its holdings in the Company on a continuing basis and may purchase or sell Common Shares in the future, including in private transactions (and, if applicable, through a marketplace), in each case depending on a number of factors. The Acquirors may formulate other purposes, plans or proposals regarding the Company or any of its securities or may change their intentions with respect to any and all matters. The Acquirors, in consultation with the Company, may also propose or seek to effect certain corporate transactions involving the Company. 

The acquisition of the Common Shares did not constitute a formal bid, and the Acquirors did not rely on any exemption from the formal bid requirements in connection with the acquisition. 

Each of Matachewan and McChip will file an early warning report in accordance with applicable securities laws, which will be available under the Company’s profile on SEDAR+ at www.sedarplus.ca. A copy of each early warning report may also be obtained by contacting Zachary Goldenberg, Chief Executive Officer of Matachewan and McChip, at 647-987-5083. 

About Matachewan Consolidated Mines, Limited 

Matachewan is a Canadian natural resource company incorporated in 1933 and headquartered in Toronto, Ontario. Matachewan maintains exposure to the natural resource sector through investments in mineral and other resource-related opportunities. Its common shares trade on the TSXV under the symbol MCMA.

About McChip Resources Inc. 

McChip is a Canadian natural resource company incorporated in 1935 and headquartered in Toronto, Ontario. McChip maintains exposure to the natural resource sector through investments in mineral and other resource-related opportunities. Its common shares trade on the TSX Venture Exchange under the symbol MCS.

For additional information, please contact: 

Matachewan Consolidated Mines, Limited: Zachary Goldenberg, Chief Executive Officer, T: 647-987-5083, E: zach@libertyvp.co

McChip Resources Inc.: Zachary Goldenberg, Chief Executive Officer, T: 647-987-5083, E: zach@libertyvp.co

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Forward-Looking Statements 

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements relating to the Acquirors’ intention to participate in the second tranche of the Offering and their future intentions with respect to their holdings in the Company. Forward-looking information is based on assumptions and is subject to risks and uncertainties, many of which are beyond the control of the Acquirors, that could cause actual results to differ materially, including that the second tranche of the Offering may not be completed on the terms anticipated or at all. Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable securities laws, the Acquirors disclaim any obligation to update or revise any forward-looking information. 

LAS VEGAS, Oct. 20, 2026 (GLOBE NEWSWIRE) — Galaxy Gaming, Inc. (OTCQX: GLXZ), a leading independent developer and distributor of casino table games and technology, today announced the appointment of John M. Boushy to its Board of Directors, effective October 21, 2026. Mr. Boushy succeeds Meredith Brill, who has informed the Board of her intention to step down after four years of distinguished service, as a Class II Director.

John M. Boushy brings more than 45 years of leadership experience in the gaming, hospitality, technology and entertainment industries. He is the Founder and Managing Member of Boushy Consulting, LLC, where he advises gaming operators, investors and senior executives on strategic, operational and development matters. Through his consulting practice, Mr. Boushy served in executive management roles with the parent company of The Cosmopolitan of Las Vegas, was an advisor to the Second Priority Noteholders Committee during the bankruptcy of Caesars Entertainment Operating Company, served on the board of Caesars Entertainment after its emergence from bankruptcy, and has served since 2015 as Co-Founder and Chairman of the parent company of ReelMetrics.

Prior to founding Boushy Consulting, Mr. Boushy served as Chief Executive Officer, President and Director of Ameristar Casinos, Inc., where he was responsible for leading all aspects of the company’s operations and growth strategy. Before joining Ameristar, he spent more than two decades with Harrah’s Entertainment, Inc., holding a series of senior executive positions including Executive Vice President of Project Development, Design and Construction, Chief Integration Officer, Chief Information Officer, and Senior Vice President of Operations, Marketing and Technology.

During his tenure at Harrah’s, Mr. Boushy oversaw enterprise-wide strategic growth initiatives, enabled by the collaboration of operations, marketing, and information technology; led the integration of the landmark merger between Harrah’s Entertainment and Caesars Entertainment, delivering twice the proforma synergies; and directed major development and capital investment projects. He is widely recognized as an innovator in the application of technology, marketing analytics and operational excellence within the gaming industry, which powers what is now Caesars Total Rewards.

“We are pleased to welcome John to the Galaxy Gaming Board of Directors,” said Mark Lipparelli, Chairman of the Board. “We are fortunate to have someone of his reputation and rare capability lend his expertise to our team. John has been a major force in the gaming industry for several decades, working alongside many of the industry’s most talented leaders and visionaries. He is personally credited with helping advance numerous innovations in gaming operations, marketing and technology throughout his distinguished career. As a senior executive, he has consistently been a demanding partner, a thoughtful collaborator and a catalyst for industry advancement. We look forward to benefiting from his experience, judgment and mentorship in the years ahead.”

Mr. Lipparelli added, “John’s extensive executive leadership experience, coupled with his background in strategic planning, technology innovation, mergers and acquisitions, operations and corporate governance, will be invaluable as Galaxy continues to execute its long-term growth strategy.”

The Board also expressed its appreciation to Meredith Brill for her dedicated service.

“We thank Meredith for her many contributions to Galaxy Gaming over the past four years,” said Mark Lipparelli. “Her insights and guidance have helped position the Company for its next phase of growth, and we wish her every success in her future endeavors.”

About Galaxy Gaming

Headquartered in Las Vegas, Nevada, Galaxy Gaming (galaxygaming.com) develops and distributes innovative games, bonusing systems, and technology solutions to physical and online casinos worldwide. Galaxy Gaming offers games proven to perform developed by gaming experts and backed by the highest level of customer support. Galaxy Gaming Digital is the world’s leading licensor of proprietary table games to the online gaming industry. Galaxy Gaming has 131 licenses worldwide, including licenses in 28 U.S. states.

SAFE HARBOR

This press release contains, and oral statements made from time to time by representatives of Galaxy may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

These forward-looking statements reflect the current views, models, and assumptions of Galaxy, and are subject to various risks and uncertainties that cannot be predicted or qualified and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances, many of which are beyond the control of the Company that may cause actual results in the Company’s performance to differ materially from those expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to risks that the termination of the Merger Agreement disrupts the Company’s current plans and operations or diverts the attention of the Company’s management or employees from ongoing business operations; the risk of potential difficulties with the Company’s ability to retain and hire key personnel and maintain relationships with customers and other third parties as a result of the termination of the Merger Agreement; the risk that the termination of the Merger Agreement may involve unexpected costs and/or unknown or inestimable liabilities; the risk that the Company’s business may suffer as a result of uncertainty surrounding the termination of the Merger Agreement; the risk of stockholder litigation; effects relating to the announcement of the termination of the Merger Agreement on the market price of the Company’s common stock; the ability of Galaxy to enter and maintain strategic alliances, product placements or installations in land based casinos or grow its iGaming business; garner new market share; secure licenses in new jurisdictions or maintain existing licenses; successfully develop or acquire and sell proprietary products; comply with regulations, changes in gaming related and non-gaming related statutes and regulations and/or self-imposed restrictions imposed on and by our customers that affect their revenues in land-based casino and online casino markets; have its games approved by relevant jurisdictions; and adapt to changes resulting from the COVID-19 or other pandemics including without limitation, government imposed shut downs, travel restrictions and supply chain interruptions; and other factors.

Additional information concerning these and other risk factors can be found in the Company’s filings with the Securities and Exchange Commission, including in the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and Definitive Proxy Statement.

All forward-looking statements made herein are expressly qualified in their entirety by these cautionary statements. While forward-looking statements reflect the good faith beliefs of the Company, they are not guarantees of future performance or events, and there can be no assurance that the actual results, events or developments referenced herein will occur or be realized. Readers are cautioned that all forward-looking statements speak only to the facts and circumstances present as of the date of this press release. Galaxy expressly disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, or new information, data or methods, future events or other changes.

Contact:

Media: 
Phylicia Middleton (702) 938-1753 

Investors:         
Steve Kopjo (702) 727-8886

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).

Q3 2026 Highlights¹

• Group revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong demand for the commercial portfolio, in line with expectations. September sales drove a higher quarterly exit rate indicating continued strength in underlying demand for Telix’s PSMA products.
• Precision Medicine revenue of US$201 million, increased 30% over the prior corresponding quarter, driven by both Gozellix® and Illuccix®². Telix’s commercial PSMA-PET imaging³ portfolio continued to strengthen its market position, driven by strong demand for our clinically differentiated products.
• U.S. Food and Drug Administration (FDA) approved Pixclara®⁴ for glioma imaging, marking a significant milestone and establishing the first approved imaging agent for this indication in the U.S.⁵. The first commercial doses were administered in September 2026⁶.
• BiPASS®, a Phase 3 study evaluating pre-biopsy prostate cancer detection, completed enrollment⁷, with the FDA supporting an NDA pathway and granting Fast Track Designation⁸.
• Telix announced a merger with Isotope Technologies Munich SE (ITM). The merger creates a leading radiopharmaceutical platform with one of the industry’s broadest therapeutics pipelines, supported by best-in-class isotope production, manufacturing, and supply chain capabilities⁹.
• Telix reaffirmed that FY 2026 revenue and other income is expected to be in excess of US$1 billion, with revenue tracking in line with upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million of other income. The Company has also revised its FY 2026 R&D expenditure guidance range to US$240 million to US$260 million.

Q3 2026 Revenue

Revenue (US$M)	Q3 2026	Q3 2025	% Change	Q2 2026	% Change
Group revenue	245	206	19%	247	(1)%
Precision Medicine revenue10	201	155	30%	202	—%
TMS revenue11	44	47	(6)%	45	(2)%

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality. We are pleased by the strong September exit run rate, supporting our confidence in delivering over 25% Precision Medicine revenue growth in 2026. We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base. During the quarter, we announced a transformative merger with ITM, creating a leading vertically integrated radiopharmaceutical company with one of the industry’s broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities. This is aligned with our long-term growth strategy reinforcing our ability to reliably serve patients at scale.”

Therapeutics Business Unit

• TLX591-Tx (¹⁷⁷Lu rosopatamab tetraxetan): Following FDA review and alignment of the Part 1 safety data, Telix is finalizing its IND amendment to the FDA to support progression to Part 2 of the ProstACT Global Phase 3 study in the U.S.¹². Outside the U.S., Part 2 of the global study continues to enroll patients across seven countries: Australia, New Zealand, Canada, Türkiye, the UK, Singapore, and South Korea. Regulatory approvals have also been obtained to proceed in China and Japan¹³.
• TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA): OPTIMAL-PSMA¹⁴, a Phase 2 study evaluating TLX597-Tx in metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer¹⁵, completed enrollment of 120 patients¹⁶. A data readout is expected in the first half of 2027. OPTIMAL-e¹⁷, a Phase 2 study evaluating TLX597-Tx in metastatic androgen pathway modulator-naive or -sensitive (mAPMN/S) prostate cancer¹⁸, continues to demonstrate strong enrollment momentum.
• TLX250-Tx (¹⁷⁷Lu girentuximab tetraxetan): Continued enrollment of patients in LUTEON¹⁹, a pivotal trial of TLX250-Tx in advanced clear cell Renal Cell Carcinoma (ccRCC). The trial is evaluating the safety and efficacy of TLX250-Tx compared with the investigator’s choice of monotherapy consistent with standard of care.

• TLX101-Tx (iodofalan ¹³¹I): Following full enrollment of the first cohort in Part 1 of the Phase 3 IPAX BrIGHT study²⁰, an IND amendment was filed with the FDA to support expansion of the trial into Part 1b in the U.S. IPAX-2²¹, a Phase 1 study of TLX101-Tx in patients with newly diagnosed glioblastoma met its primary endpoint, establishing a maximum tolerated dose (MTD) of two 5 GBq cycles in combination with standard of care. No dose-limiting toxicities were observed, supporting advancement of IPAX-2 to Phase 2²².

Precision Medicine Business Unit

⁶⁸Ga-PSMA-11 for prostate cancer imaging:

• BiPASS®, a Phase 3 study of ⁶⁸Ga-PSMA-11 PET in combination with MRI for the diagnosis of prostate cancer in the pre-biopsy setting, completed enrollment of 350 patients. Rapid enrollment underscores the unmet need for a minimally invasive option for prostate cancer diagnosis. The study builds on the clinical foundation established by the PRIMARY²³ and PRIMARY2²⁴ studies and is intended to support regulatory submissions. The FDA has supported an NDA pathway that could facilitate reimbursement and granted Fast Track Designation, which may enable an expedited review.
• With enrollment complete in the Phase 3 registrational study of TLX591-Px (Illuccix) in Japan²⁵, Telix is preparing for NDA submission and potential market entry. A Conditional Approval is currently under review by Japan’s Pharmaceutical and Medical Devices Agency (PMDA) and is expected to facilitate an expedited review process.

TLX101-Px (floretyrosine F 18) for brain cancer imaging:

• Telix’s Marketing Authorization Application (MAA) for Pixlumi®²⁶ in Europe remains under review.
• Following the FDA clearance of the IND application, Telix is advancing a Phase 3 registrational study to support expansion of the Pixclara label for the diagnosis of brain metastases.

TLX250-Px, Zircaix®²⁷ (⁸⁹Zr-girentuximab senvedoxam) for kidney cancer imaging:

• Following receipt of the corrected Complete Response Letter (CRL), Telix is finalizing its Biologics License Application (BLA) resubmission package, addressing the remaining third-party manufacturing observations. Resubmission to the FDA is planned in the near term and remains a top priority for the Company in 2026.

Telix Manufacturing Solutions (TMS)

• Through RLS, Telix has established a growing network of micro-pharmacy sites, known as UroOncRx™, providing urologists with onsite access to our imaging agents, particularly in underserved and remote markets. Multiple sites are now operational and dispensing product, further strengthening our radiopharmacy infrastructure and expanding patient access.
• ARTMS, a Telix company, has secured contracts for 50 QUANTM® Irradiation Systems (QIS®) globally, achieving a key commercial milestone and reflecting continued demand for its isotope production technology.
• Telix announced a collaboration with Ekalia²⁸, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, to advance scalable U.S. production of astatine-211 (²¹¹At), an alpha-emitting radioisotope being investigated for targeted alpha therapy. The first IBA alpha-beam cyclotron installation at Telix’s RLS Radiopharmacies site in Trevose near Philadelphia (PA) is intended to establish a reproducible production model, with the potential for further rollout across the RLS network as demand develops. The collaboration secures long-term, priority isotope access for Telix’s alpha therapy pipeline, while also supporting third-party academic and industry programs.

Corporate Updates

• Telix announced a transformational merger with ITM, the world’s leading supplier of therapeutic radioisotopes, reinforcing its long-term strategy as a vertically integrated radiopharmaceutical company and further strengthening one of the industry’s broadest therapeutic pipelines. ITM brings a complementary late-stage portfolio led by ITM-11 (¹⁷⁷Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), as well as industry-leading isotope capabilities anchored by the only globally scaled commercial-grade ¹⁷⁷Lu production platform. The transaction includes upfront consideration of US$1.65 billion on a cash-free, debt-free basis, with ITM shareholders expected to receive approximately US$1.25 billion in Telix shares released as ADRs. Additional contingent consideration of up to US$700 million may be paid upon achievement of future regulatory approvals and commercial sales milestones for ITM-11. The transaction remains subject to Telix shareholder approval and customary closing conditions. A General Meeting of Shareholders is expected to be held on December 1, 2026 (AEDT).
• Mr. David Gill was appointed Chair of the Board on September 1, 2026²⁹. Mr. Gill is a life sciences executive with more than 35 years of experience in biopharma, radiopharmaceuticals and medical devices. He has held senior leadership positions, including President, Chief Operating Officer and Chief Financial Officer roles at multiple public companies, and brings extensive expertise in capital markets, governance, business scaling and corporate strategy. He currently serves on the boards of several healthcare companies and holds degrees from Wake Forest University and Emory University.
• Mr. Marcin Firek will join Telix as Company Secretary, effective October 21, 2026. Mr. Firek brings extensive experience in corporate governance, legal affairs, risk management and public company administration, including for dual-listed Australian and U.S. companies. Most recently, he served as Head of Enterprise & Operational Risk at PwC Australia. Previously, he led the Company Secretary team at Woolworths Group Limited, ASX Limited and James Hardie Industries Plc. Earlier in his career, he practiced corporate and M&A law at MinterEllison. Mr. Firek will be the primary person responsible for communications with the ASX under ASX Listing Rule 12.6. Mr. Shomalin Naidoo has also ceased his appointment as interim Company Secretary effective today.

FY 2026 guidance

• Telix expects FY 2026 revenue and other income to exceed US$1 billion, with revenue tracking toward the upper end of its FY 2026 guidance of US$950 million to US$970 million, including US$40 million in other reported income.
• Revenue guidance reflects product sales in markets where marketing authorization has been granted, includes a full-year contribution from RLS, and incorporates anticipated sales of Pixclara.
• Telix revises its FY 2026 R&D expenditure guidance range to US$240 million to US$260 million, previously US$230 million to US$270 million, subject to the achievement of planned clinical, regulatory and development milestones.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix’s commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. FDA, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma imaging. The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan ¹³¹I) in recurrent glioblastoma, and TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Investor Relations Annie Kasparian Annie.kasparian@telixpharma.com Charlene Jaw Charlene.jaw@telixpharma.com

Media Eliza Schleifstein Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

_____________________________________________ 1 The financial information for the quarter ended September 30, 2026 is unaudited. 2 Illuccix® (kit for the preparation of gallium-68 gozetotide injection). Gozellix® (kit for the preparation of gallium-68 gozetotide injection). 3 Imaging of prostate-specific membrane antigen with positron emission tomography. 4 Pixclara® (floretyrosine F 18). 5 Telix ASX disclosure September 14, 2026. 6 Telix press release October 6, 2026. 7 Telix ASX disclosure September 2, 2026. ClinicalTrials.gov ID: NCT07052214. 8 Telix ASX disclosure September 30, 2026. 9 Telix ASX disclosure September 21, 2026. 10 Primarily sales of Illuccix and Gozellix in our Precision Medicine business. 11 Telix Manufacturing Solutions (TMS) third-party revenue predominantly driven by RLS Radiopharmacies (RLS), excludes Illuccix and Gozellix sales and TMS inter-segment revenue. 12 Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345. 13 Telix ASX disclosure December 17, 2025. 14 Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437. 15 Formerly known as metastatic castration-resistant prostate cancer (mCRPC). 16 Telix LinkedIn June 25, 2026. 17 Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336. 18 Formerly known as metastatic hormone-sensitive prostate cancer (mHSPC). 19 ClinicalTrials.gov ID: NCT07197580. 20 ClinicalTrials.gov ID: NCT07100730. 21 ClinicalTrials.gov ID: NCT05450744 22 Telix media release May 19, 2026. 23 Emmett et al. Eur Urol. 2021. 24 Buteau et al. Lancet Oncol. 2026. ClinicalTrials.gov ID: NCT05154162. 25 Telix media release July 17, 2026. 26 Brand name subject to final regulatory approval. 27 Brand name subject to final regulatory approval. 28 Telix media release October 19, 2026. 29 Telix ASX disclosure September 1, 2026.

Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

20. Oct 2026 / 23:54 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Natural Person

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

20. Oct 2026 / 23:52 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Natural Person

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

20. Oct 2026 / 23:51 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Natural Person

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

20. Oct 2026 / 23:50 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Natural Person

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

TORONTO, Ontario, Oct. 20, 2026 (GLOBE NEWSWIRE) — Cadillac Mines Corporation (TSX: CADY), (“Cadillac Mines” or the “Company“) is pleased to announce assay results from exploration diamond drilling at the Moriss Zone on its 100%-owned Galloway Project (“Galloway”), located approximately 30 kilometres west of Rouyn-Noranda, Quebec. The Moriss Zone is situated approximately 400 m west of the main intrusion-related Galloway trend and consists predominantly of vein hosted stringer to disseminated pyrite mineralization sitting within moderately dipping shear zones.

These first results from the Company’s inaugural Galloway diamond drill program, following the April 2026 acquisition of Fokus Mining Corporation, confirm gold mineralization down-dip of previous drilling on the Moriss-1 and Moriss-2 shears and identify a third mineralized shear, Moriss-3.

Results are reported for a total of three holes totalling 2,592 metres from the 2026 exploration drilling at Moriss. The Moriss drilling forms part of a 27,500 metre 2026 exploration program across the entire Galloway Property.

Moriss Zone Drilling Highlights

Selected highlight results include:

• 10.96/t Au over 4.4 m estimated true width (ETW) in hole GAL26-003, and
• 8.02 g/t Au over 3.2 m estimated true width (ETW) in hole GAL26-003, and
• 6.81 g/t Au over 3.6 m estimated true width (ETW) in hole GAL26-003
• 11.26 g/t Au over 1.0 m estimated true width (ETW) in hole GAL26-004, and
• 4.53 g/t Au over 2.2 m estimated true width (ETW) in hole GAL26-004

Kerry Sparkes, Senior Vice President, Exploration of Cadillac Mines, stated, “Our first holes at Galloway have confirmed that gold mineralization continues at depth down-dip of previous drilling on Moriss-1 and Moriss-2, thereby identifying a third, deeper shear.” Mr. Sparkes continued. “Moriss-3 sits below previous drilling and gives us a new high grade mineralized shear to test in 2027.”

Geology and Context of Results

The Galloway property is located in the Abitibi greenstone belt in Quebec, seven kilometres east of the Quebec-Ontario border and 13 kilometres northeast of the Company’s Kerr-Addison project (Figure 1).

The Property is underlain by mafic to felsic metavolcanic rocks of the Archean Blake River Assemblage and, in the south of the property, by the volcanic and metasedimentary rocks of the Timiskaming Assemblage. The Baie Renault intrusive complex, a large Archean syenite complex emplaced in the Blake River Assemblage, occupies much of the property. Younger, Proterozoic-age Cobalt Group sedimentary rocks lie unconformably over the southern part of the property. Galloway extends from 400 metres to 4.5 kilometres north of the Larder Lake-Cadillac Deformation Zone (“LLCDZ”), a major east-west structure hosting many of the region’s gold deposits. Northeast and northwest-trending brittle faults cut the Archean and Proterozoic rocks.

The main mineralization style is an intrusion-related gold-copper-molybdenum magmatic-hydrothermal system interpreted to be related to the Baie Renault intrusive complex. Three main mineralized zones have been identified on the western part of the property: Moriss, Hendrick and GP-Hurd.

Hendrick and GP-Hurd are characterized by broad zones of gold and copper mineralization in the syenite and adjacent tuff units. Mineralization is associated with disseminated pyrite and quartz-carbonate veins and veinlets hosting chalcopyrite, often accompanied by molybdenite.

Moriss is the westernmost zone on the property. Unlike Hendrick and GP-Hurd, gold mineralization at Moriss is hosted in three successive EW shear zones Moriss-1, Moriss-2 and the recently identified Moriss-3, spaced approximately 100 to 200 metres apart. The shears are hosted in the Blake River volcanic sequence and are characterized by quartz-carbonate veins with sericite-silica-carbonate alteration and pyrite.

The holes reported in this release were drilled at Moriss to test both lateral and down-dip extensions. Drilling started in June 2026 and was completed in early August. Before this program, only Moriss-1 and Moriss-2 had been identified. Drilling further south, beyond the known shears, identified a third mineralized shear, Moriss-3.

• Hole GAL26-003 (Figures 2, 3 and 4) was the first hole drilled on Moriss to test the western extension of Moriss-1 and Moriss-2. The hole remained in Blake River basalts for most of its length and intersected Moriss-1 and Moriss-2 shears where projected from previous drilling. Moriss-1 returned 8.02 g/t Au over 3.2 m ETW, approximately 150 m below surface and Moriss-2 returned 10.96 g/t Au over 4.4 m ETW, approximately 225 m below surface. In both shears, gold is associated with quartz-carbonate veins and pyrite. Approximately 200 metres further south, the hole intersected Moriss-3, which returned 6.81 g/t Au over 3.6 m ETW in previously untested ground.
• Holes GAL26-004 and GAL26-006 (Figures 2; 3 and 5) were drilled toward the eastern margin of Moriss as defined by previous drilling. Both holes intersected Moriss-1 where projected from previous drilling, approximately 165 m and 335 m below surface, respectively. The shear was present in both holes but less strongly mineralized than in GAL26-003. Moriss-1 returned 1.31 g/t Au over 0.8 m ETW in GAL26-004 and 1.63g/t Au over 2.1 m ETW in GAL26-006. GAL26-004 also intersected Moriss-2, which returned 4.53 g/t Au over 2.2 m ETW. In GAL-26-006, two shear zones were intersected at approximately 520 and 560 metres downhole, with both carrying trace gold. The nearest hole intersecting Moriss-2 is approximately 300 metres away, and the correlation of either shear with Moriss-2 has not yet been established. Near the top of GAL26-004, an interval of 11.26 g/t Au over 1.0 m core length is not associated with a shear zone, rather it is associated with pyrite mineralization along pillow margins in the basalt.

Exploration drilling at Moriss is complete for 2026. The Company expects to resume drilling at Moriss in the first quarter of 2027 to follow up on Moriss-3 and test the other two shears along their lateral extent and at depth.

Figure 1

Plan Map showing the location of the Galloway property relative to Cadillac Mines’ other projects and overall land position.

Figure 2

Plan map of the western part of the Galloway property with location and traces of the drill holes reported in this release and section locations.

Figure 3

Inclined longitudinal section A-A’ looking north, showing gold composites on the Moriss zone. Drill holes reported in this release are highlighted on the figure.

Figure 4

Cross section B-B’ looking east, showing drill hole GAL26-003 and the projections of the Moriss shear zones. Reported intervals are estimated true width.

Figure 5

Cross section C-C’ looking east, showing drill holes GAL26-004 and GAL26-006 and the projections of the Moriss shear zones. Reported intervals are estimated true width.

Table 1. Selected Significant Results

Hole ID		From (m)	To (m)	Downhole Interval (m)	ETW (m)	Au (g/t)
							Horizon
GAL26-003	Incl.	186.5	189.9	3.4	3.2	8.02	Moriss-1
		186.5	187.8	1.3	1.2	17.91
		295.4	300.0	4.6	4.4	10.96	Moriss-2
	Incl.	297.2	298.9	1.7	1.6	26.85
		385.9	387.0	1.1	1.1	1.32
		413.5	415.0	1.5	1.4	1.05
		460.9	461.8	0.9	0.9	1.12
		486.0	489.7	3.7	3.6	6.81	Moriss-3
	Incl.	486.0	487.0	1.0	1.0	18.52
		496.0	498.5	2.5	2.5	1.18
		588.0	588.9	0.9	0.9	6.28
GAL26-004		115.0	116.0	1.0	1.0	11.26	Pyrite in pillow basalts
		209.2	210.0	0.8	0.8	1.31	Moriss-1
	Incl.	361.0	363.2	2.2	2.2	4.53	Moriss-2
		361.0	362.0	1.0	1.0	7.74
		592.0	593.2	1.2	1.2	1.02
GAL26-006		360.6	363.0	2.4	2.1	1.63	Moriss-1
		375.0	376.0	1.0	0.9	1.59
		761.0	762.0	1.0	0.9	1.25

Notes on Table 1:

1. Estimated True Widths (ETW) are estimated based on the average orientation of the Moriss shear zones – Dip: -50 / Dip direction:12.
2. The composite assay grades presented in the summary tables are calculated using a minimum average of 1.00 g/t for Au, with a maximum of 3.0 m internal waste and no grade capping.

Table 2. Drill hole locations

Drill Hole	Easting	Northing	Elevation (masl)	Azimuth (°)	Dip (°)	Total Length (m)	Zone
GAL26-003	617104	5339170	283	210	-57	606	Moriss
GAL26-004	617308	5339156	288	210	-50	1191	Moriss
GAL26-006	617402	5339329	286	205	-68	795	Moriss

Notes on Table 2:

1. Table contains information for 2026 diamond drill holes of the Moriss program with selected results presented in Table 1.
2. Coordinate system NAD83 UTM Zone 17N.

2026 Exploration Summary and Outlook

Galloway is Cadillac Mines’ flagship project in Quebec. In 2026, Cadillac is executing its largest ever annual drill campaign, targeting the completion of over 145,000 meters of diamond drilling across its entire property portfolio, including Larder and Galloway, at a budgeted cost of approximately $65 million. Through the end of September 2026, Cadillac Mines completed 105,927 metres of drilling, representing 73% of the full-year target. Currently, Cadillac is operating 12 diamond drill rigs, with four focused on expanding mineralization at its newly acquired Galloway Project, two at Kerr-Addison focused on infill and expansion drilling, five targeting expansionary drilling at Larder, and one currently testing below the known mineralization at the Geminid Nickel target.

During the fourth quarter, Cadillac Mines will also be planning and implementing a property wide airborne full tensor gradient magnetic survey covering the Larder, Galloway and Kerr properties along with a ground based deep penetrating MT geophysical survey. In addition, Cadillac has contracted Geologic AI to scan over 40,000 m of historic Galloway core from the 400-hole historical diamond drill database, collecting continuous XRF chemistry plus hyperspectral mineralogy to aid in the geologic interpretation and re-assaying of select intervals of core for Copper and Molybdenum.

Quality Assurance and Quality Control Procedures

Cadillac Mines maintains an internal quality assurance and quality control (QA/QC) program at the Galloway Project to ensure sampling and analysis of all exploration work is conducted in accordance with industry-standard best practices.

Drill core is logged and sampled at core logging facilities in Virginiatown under the supervision of a Qualified Geologist. Sample intervals are selected by a geologist based on geological observations, with sample numbers, certified reference materials (CRMs), and blanks inserted into the sample sequence and recorded in the database. Drill core is cut in half using an automated core saw equipped with a diamond-tipped blade. One half of the core is placed in labelled plastic sample bags and then packaged in rice bags for shipment, while the remaining half is returned to the core box and retained for future reference. Saws and surrounding areas are thoroughly cleaned at the end of every shift and between each hole.

Core samples are transported by Manitoulin Transport to ALS Geochemistry in Thunder Bay or Rouyn-Noranda for sample preparation and gold analysis and then shipped to ALS Geochemistry in North Vancouver for multi-element analysis. Sample preparation includes crushing the sample to at least 70% passing 2 mm. A 500 g sub-sample is collected using a riffle splitter, transferred into a sealed and uniquely coded jar, and analyzed for gold by Photon Assay. A second sub-sample of up to 250 g is collected using a riffle splitter, pulverized to at least 85% passing 75 microns, and analyzed for multi-element chemistry using four-acid digestion of a 0.25 g analytical split with an ICP-AES finish.

Cadillac Mines inserts CRMs (5%), blanks (5%), and duplicate (5%) samples into the sample stream to monitor analytical accuracy, contamination, and sampling precision. ALS Laboratories are an ISO/IEC accredited laboratory and maintain internal quality control procedures, including the insertion of laboratory blanks, reference materials, and pulp duplicates.

Qualified Person

Mr. Clayton Pearson, P.Geo is Cadillac’s Senior Project Manager and the Qualified Person who has approved the technical information disclosed in this release.

About Cadillac Mines

Cadillac Mines Corporation is a Canadian mineral exploration company advancing a growing portfolio of gold and critical mineral projects along the prolific Cadillac-Larder Lake Break in Ontario and Québec. Anchored by the historic Kerr-Addison Mine, the Company is focused on expanding its gold resource base, advancing the Geminid nickel deposit and unlocking the broader potential of its district-scale Abitibi land position. Through disciplined exploration, technical excellence and responsible development, Cadillac Mines is working to create lasting value for shareholders, communities and other stakeholders. For more information about the Company, please visit www.cadillacmines.com.

Additional Information

For further information, please contact:

Hannes Portmann, Chief Financial Officer
hportmann@cadillacmines.com

Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to future development plans and the business and operations of the Company. Forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold, silver, base metals or certain other commodities; fluctuations in currency markets; results of exploration; the economics of processing methods; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, cave-ins and flooding); inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/45cb517c-a766-413a-832a-f335d6cab57f

https://www.globenewswire.com/NewsRoom/AttachmentNg/78d3f1dc-8272-4399-800a-74dcb12ba99e

https://www.globenewswire.com/NewsRoom/AttachmentNg/6e41b940-9718-4b3e-9701-5115a1cdb5fe

https://www.globenewswire.com/NewsRoom/AttachmentNg/8048d4d2-646e-4d70-ae1b-04b0782f76c4

https://www.globenewswire.com/NewsRoom/AttachmentNg/fcf3e711-5c01-46da-a895-4309a2e895a0